From: Jeffrey Port II=In To: [email protected] Cc: 'PW F' Subject: Date: Thu, 02 Jul 2015 14:41:30 +0000 Attachments: Angiocrine_Bioscience_Confidential_NUMBERS_deck_Jun_2015_v 150701.pptx Jeff Hope all well Wanted to provide the numbers for Angiocrine In summary, we are heading out by summers end for a series B raise at a 50 million pre money valuation. We are offering a 25% discount to the series b, and looking to bolster our financials for the raise with an additional 5 million in capital. Overall, I think a very good deal . Paul Finnegan , our CEO, and I are available next week in NY if you wish to discuss live If you have interest let me know Best regards Jeff Port (c) EFTA00852631